What Are Peptides? A Plain-English Guide

If you have landed here, you have probably seen “peptides” used to describe wildly different things: a blockbuster weight-loss injection, a recovery compound athletes inject into a sore knee, an anti-aging serum, a sleep aid. They can’t all be the same thing — and they aren’t. The word peptide describes a type of molecule, not a category of product, an effect, or a safety profile. Once that distinction clicks, the whole confusing landscape gets a lot easier to read.

What a peptide actually is

A peptide is a short chain of amino acids — the small molecules that are the building blocks of all proteins. Amino acids link together like beads on a string, and a string of a few up to a few dozen beads is a peptide. Make the string much longer and fold it into a complex three-dimensional shape and you have a protein.

Crucially, peptides are not exotic. Your body manufactures thousands of its own and uses them as chemical messengers — molecules that carry instructions from one part of the body to another. Insulin, which tells cells to take up glucose, is a peptide. So are many of the hormones that govern hunger, growth, mood, and reproduction. When people talk about “peptide therapy,” they are almost always talking about lab-made copies (or close analogs) of these naturally occurring signaling molecules, used to nudge a particular biological pathway in a desired direction.

That is the honest one-sentence version: most therapeutic peptides are synthetic versions of the body’s own signals. What any specific peptide does, how well it does it, and whether that has been proven in humans varies enormously from one compound to the next.

Peptides vs proteins (and where the FDA draws the line)

In everyday science the difference between a peptide and a protein is loose — basically “small chain” versus “big chain.” But because the distinction decides how a compound is regulated, the US Food and Drug Administration drew a precise, bright line. In its rulemaking on what counts as a “biological product,” the FDA settled on a size cutoff: an amino-acid chain of 40 or fewer amino acids is treated as a peptide and regulated as a drug, while a chain greater than 40 amino acids is treated as a protein and regulated as a biologic.

Note: This 40-amino-acid line is a regulatory convenience, not a law of nature. It exists so that companies and the agency have a clear rule for which approval pathway a molecule follows. It is also why so many “peptide” compounds — short chains — are discussed as drugs rather than biologics.

This is more than trivia. It explains why peptides occupy their own corner of the regulatory world: they are small enough to often be made by chemical synthesis rather than grown in living cells, which is part of what makes them attractive to compounding pharmacies and, less happily, to the gray-market manufacturers who sell unapproved “research” material.

”Peptide therapy” — what people usually mean

“Peptide therapy” is a marketing umbrella, not a precise medical term. In practice it usually refers to using peptide compounds — most often by subcutaneous injection, sometimes as a nasal spray, topical cream, or oral form — to pursue a goal such as faster recovery, fat loss, better sleep, improved skin, or a general “anti-aging” effect.

Because the umbrella is so wide, the phrase tells you almost nothing on its own. It stretches from a clinician prescribing an FDA-approved drug for an approved condition, all the way to someone self-injecting an unapproved compound of uncertain origin based on a protocol found on a forum. Those are not remotely the same activity, even though both might get called “peptide therapy.” The useful questions are always: which peptide, for what, prescribed by whom, and from where? For a deeper look at the biology — how these compounds are thought to signal once they’re in the body — see our companion guide on how peptide therapy works.

The main categories used in the US

It helps to group the peptides people actually ask about into a handful of families. This is a map, not an endorsement — inclusion here says nothing about whether a compound is proven or legal.

• Metabolic / weight-loss peptides (GLP-1s). The most prominent and best-evidenced group. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved prescription drugs with large clinical trials behind them. These are the proven end of the peptide spectrum. Explore them in weight-loss peptides explained.
• Healing & recovery peptides. BPC-157 and TB-500 are the headline names, marketed for tendon, muscle, and gut repair. The evidence here is largely preclinical (animal and lab studies); neither is FDA-approved, and human data is thin. See healing peptides explained and what is BPC-157?.
• Growth-hormone secretagogues. Compounds like sermorelin, CJC-1295, ipamorelin, and tesamorelin that prompt the body to release its own growth hormone, used for recovery, body composition, and anti-aging. Of these, only tesamorelin (Egrifta) is FDA-approved, and only for a specific HIV-related condition; the rest are unapproved for these uses.
• Sexual-health peptides. PT-141 (bremelanotide) acts on desire pathways in the brain. It is FDA-approved as Vyleesi for one narrow indication; broader use is off-label or compounded.
• Cosmetic / skin peptides. GHK-Cu (copper peptide) is best known as a topical cosmetic ingredient with a modest skin-care evidence base, distinct from its unproven injectable form.
• Nootropic peptides. Selank and Semax are marketed for focus, anxiety, and cognition. They are not FDA-approved and rest mostly on Russian-origin research.
• Immune & “other” peptides. Thymosin alpha-1 is used for immune support and is approved as a medicine in some countries, though not by the FDA for general use.

The honest headline across this map: a small number of peptides are approved, trial-backed medicines, and the large majority are not. Treating “peptides” as one trustworthy category is the single most common mistake people make.

Approved drugs vs gray-market “research” peptides

This is where most of the real-world confusion — and risk — lives. The same molecule can reach a person through very different channels:

1. An FDA-approved finished drug, manufactured to pharmaceutical standards, prescribed by a licensed provider, dispensed by a pharmacy. This applies to a handful of peptides (the GLP-1s, tesamorelin, bremelanotide).
2. A compounded preparation made by a licensed compounding pharmacy for a specific patient with a valid prescription — a legitimate but more tightly regulated route, and one that is in flux in 2026 (more below). Our explainer on 503A vs 503B compounding covers how that system works.
3. “Research use only” (RUO) vials sold online and explicitly labeled not for human use. These are the gray market. The label is not a technicality: such products are not made to drug standards, their actual purity and concentration are unverified, and a vial may contain less, more, or something other than what’s on the sticker. A “standard” internet dose applied to an unverified product is still unsafe, because you don’t know what’s in the vial.

The takeaway is that how you obtain a peptide can matter as much as which peptide it is. An approved drug used under medical supervision and an anonymous online vial of the “same” compound are not equivalent in quality, oversight, or safety.

Where US law stands in 2026

Because peptides aren’t one legal thing, their legal status is genuinely mixed, and 2026 is an unusually active year for it.

The approved peptides — the GLP-1s, tesamorelin, bremelanotide — are ordinary prescription drugs: legal, with a prescription, for their approved uses.

The unapproved wellness peptides are the moving part. For years, several were on the FDA’s “Category 2” list — bulk substances the agency had flagged as raising significant safety concerns for compounding, which effectively kept them out of the lawful compounding market. In April 2026, the FDA announced it was removing 12 of these peptides from Category 2 (including BPC-157 and TB-500), with the removal taking effect about a week later.

It is easy to misread that as “they’re now approved” or “back on the allowed list” — and a lot of vendor copy does exactly that. It isn’t accurate. Removal from Category 2 does not, by itself, authorize compounding. Before any of these substances can be lawfully compounded from bulk, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) must review them — a meeting is scheduled for July 23–24, 2026 for the first batch — and even a favorable committee vote only advises the FDA, which must then go through formal rulemaking before anything is permanently added to the allowed (“Category 1”) list. In short: as of this writing the door has been unlocked for review, not opened.

Note: Status here is current as of June 2026 and is changing. Treat any “now legal to compound” claim about BPC-157, TB-500, or similar peptides with caution until the PCAC review and subsequent rulemaking actually conclude.

For the full timeline and what each step means, see the 2026 FDA peptide reclassification, and for the broader legal picture — including the gray-market question — see our pillar guide, are peptides legal in the US?

How to think about peptides sensibly

If you take one thing from this page, make it this: the word “peptide” is a description of chemistry, not a stamp of approval. Before drawing any conclusion about a specific compound, it’s worth separating four different questions that marketing tends to blur together:

• What is it? A specific named peptide, with its own evidence and risk profile — start with the relevant “What is …?” page.
• Does it work, and is that proven in humans? For most wellness peptides the honest answer is “promising in the lab, unproven in people.”
• Is it approved, and is there a legal route to it? A few are; most aren’t, and that route is shifting in 2026.
• Where would it actually come from? An approved pharmacy product and an anonymous online vial are not the same thing.

Keep those four straight and the peptide landscape stops being a single hyped blob and becomes what it really is: a wide spectrum of distinct compounds, a small slice of which are genuinely proven medicines and the rest of which range from “interesting but unproven” to “actively risky.” The rest of this site is built to help you tell them apart, one compound at a time.

This guide is educational and not medical advice. It does not provide dosing protocols or sourcing information, and it does not sell, supply, or prescribe any compound. Regulatory details are current as of the date above and may change.